The production site of the Russian pharmaceutical company NovaMedica will be chosen in the 1st quarter of 2013

   
•        NovaMedica is a new pharmaceutical company, established as an integral part of the $760 million collaboration between the Russian high-technology investment fund RUSNANO and the American health care venture fund Domain Associates LLC.
   
•        NovaMedica was formed specifically to be the development, marketing and operational arm, taking the highly innovative next-generation products from the collaboration, and commercializing them in Russia and the CIS.

   Moscow, November 12, 2012 – The identification of location of the production site of a new pharmaceutical company NovaMedica, a joint enterprise betweenthe Russian high-technology investment fund RUSNANO and the American venture healthcare fund Domain Associates will be chosen at the end of the first quarter of 2013.

   RUSNANO was established in March 2011 as an open joint stock company through the reorganization of the state corporation Russian Corporation of Nanotechnologies. RUSNANO's mission is to develop the Russian nanotechnology industry through co-investment in nanotechnology projects with substantial economic potential or social benefit. The Government of the Russian Federation owns 100 percent of the shares in RUSNANO. Work to establish a nanotechnology infrastructure and training for nanotechnology specialists, formerly conducted by the Russian Corporation of Nanotechnologies, has been entrusted to the Fund for Infrastructure and Educational Programs, a non-commercial fund also established through the reorganization of the Russian Corporation of Nanotechnologies.

   About Domain Associates

   Founded in 1985, Domain Associates, L.L.C. is a venture capital firm with an exclusive focus on life sciences. With $2.4 billion of capital under management, Domain is headquartered in Princeton, NJ with a second office in San Diego, CA. Domain’s three major investment segments are pharmaceuticals, specialty pharmaceuticals, and medical devices, while additional areas of interest include biomaterials, bioinstrumentation, and diagnostics.The Partners of Domain have a total of close to 200 person-years of experience among them in the healthcare/venture capital industries and have been involved in the formation and growth of more than 235 life-sciences companies.  The highly focused network, experience, and reputation of this team have made it one of the top private-equity groups participating in the healthcare field.

   Contacts:

   Telephone: +7-495-545-39-12

   E-mail:

   Web-site: www.novamedica.com